Genflow Biosciences PLC Announces Holding(s) in Company - 1
Genflow Biosciences PLC has reported a significant change in shareholding, with Premier Miton Group plc crossing a notification threshold on January 9, 2025. The investment firm now holds 15,147,262 voting rights, representing 4.33142% of the company's total voting rights, down from their previous position of 9.15053%.
The change was due to an acquisition or disposal of financial instruments, as reported through a standard TR-1 form. The notification was formally submitted on January 10, 2025, with Premier Fund Managers , a controlled undertaking of Premier Miton Group plc, being the entity holding the voting rights.
Genflow Biosciences PLC ha riportato un cambiamento significativo nella propria azionariato, con Premier Miton Group plc che ha superato una soglia di notifica il 9 gennaio 2025. La società di investimento detiene ora 15.147.262 diritti di voto, corrispondenti al 4,33142% del totale dei diritti di voto dell'azienda, in diminuzione rispetto alla loro posizione precedente del 9,15053%.
Il cambiamento è stato causato da un'acquisizione o cessione di strumenti finanziari, come riportato attraverso un modulo standard TR-1. La notifica è stata formalmente presentata il 10 gennaio 2025, con Premier Fund Managers, un'impresa controllata da Premier Miton Group plc, che è l'entità che detiene i diritti di voto.
Genflow Biosciences PLC ha informado un cambio significativo en la propiedad de las acciones, con Premier Miton Group plc superando un umbral de notificación el 9 de enero de 2025. La firma de inversión ahora posee 15,147,262 derechos de voto, lo que representa el 4.33142% del total de derechos de voto de la empresa, una disminución respecto a su posición anterior de 9.15053%.
El cambio se debió a una adquisición o disposición de instrumentos financieros, según lo informado a través de un formulario estándar TR-1. La notificación fue formalmente presentada el 10 de enero de 2025, siendo Premier Fund Managers, una entidad controlada por Premier Miton Group plc, quien tiene los derechos de voto.
Genflow Biosciences PLC는 Premier Miton Group plc가 2025년 1월 9일 통지 임계값을 초과하여 주주 구조에 중대한 변화를 보고했습니다. 이 투자 회사는 현재 15,147,262표의 투표권을 보유하고 있으며, 이는 회사 총 투표권의 4.33142%에 해당하며, 이전의 9.15053%에서 감소한 수치입니다.
변화는 재무 상품의 인수 또는 처분으로 인해 발생했으며, 표준 TR-1 양식을 통해 보고되었습니다. 이 통지는 2025년 1월 10일에 공식적으로 제출되었고, Premier Miton Group plc의 자회사인 Premier Fund Managers가 투표권을 보유하고 있는 주체입니다.
Genflow Biosciences PLC a rapporté un changement significatif dans l'actionnariat, Premier Miton Group plc ayant franchi un seuil de notification le 9 janvier 2025. La société d'investissement détient désormais 15 147 262 droits de vote, représentant 4,33142% du total des droits de vote de l'entreprise, contre 9,15053% auparavant.
Ce changement était dû à une acquisition ou à une cession d'instruments financiers, comme l'indique un formulaire standard TR-1. La notification a été formellement soumise le 10 janvier 2025, avec Premier Fund Managers, une entreprise contrôlée par Premier Miton Group plc, étant l'entité détentrice des droits de vote.
Genflow Biosciences PLC hat eine erhebliche Änderung in der Aktionärsstruktur bekannt gegeben, wobei Premier Miton Group plc am 9. Januar 2025 einen Benachrichtigungsgrenzwert überschritten hat. Die Investmentgesellschaft hält nun 15.147.262 Stimmrechte, was 4,33142% der gesamten Stimmrechte des Unternehmens entspricht, was einen Rückgang von ihrer vorherigen Position von 9,15053% bedeutet.
Die Änderung ergab sich aus dem Erwerb oder der Veräußertung von Finanzinstrumenten, wie über ein Standard-TR-1-Formular berichtet wurde. Die Benachrichtigung wurde am 10. Januar 2025 formell eingereicht, wobei Premier Fund Managers, ein kontrolliertes Unternehmen von Premier Miton Group plc, die Stimmrechte hält.
- None.
- Premier Miton Group reduced its stake from 9.15% to 4.33%, indicating significant institutional selling
TR-1: Standard form for notification of major holdings
LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 / 1. Issuer Details
ISIN
GB00BP2C3V08
Issuer Name
GENFLOW BIOSCIENCES PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
Premier Miton Group plc
City of registered office (if applicable)
GUILDFORD
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
09-Jan-2025
6. Date on which Issuer notified
10-Jan-2025
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
Resulting situation on the date on which threshold was crossed or reached | 4.331420 | 0.000000 | 4.331420 | 15147262 |
Position of previous notification (if applicable) | 9.150527 | 0.000000 | 9.150527 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 |
| 15147262 |
| 4.331420 |
Sub Total 8.A | 15147262 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
| |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
| ||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
Premier Miton Group plc | Premier Miton Group Plc |
|
|
|
Premier Miton Group plc | Premier Asset Management Midco Ltd |
|
|
|
Premier Miton Group plc | Premier Asset Management Holdings Ltd |
|
|
|
Premier Miton Group plc | Premier Asset Management Limited |
|
|
|
Premier Miton Group plc | Premier Investment Group Ltd |
|
|
|
Premier Miton Group plc | Premier Fund Managers Ltd | 4.331420 |
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
10-Jan-2025
13. Place Of Completion
Guildford, UK
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com .
SOURCE: Genflow Biosciences PLC
View the original press release on accesswire.com
FAQ
What is Premier Miton Group's current stake in Genflow Biosciences (GENFF) as of January 2025?
How much did Premier Miton Group reduce its holdings in GENFF?
When did Premier Miton Group cross the reporting threshold for GENFF?
Which Premier Miton Group entity holds the direct voting rights in GENFF?
